The role of abdominal adiposity and insulin resistance in dyslipidemia of chronic renal failure

American Journal of Kidney Diseases

Volumn 29, Issue 1, 1997, Pages 54-65

  Lee, P ^a   O'Neal, D ^a   Murphy, B ^a   Best, J ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

body fat distribution; Dyslipidemia; insulin resistance

Indexed keywords

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY FAT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS; HUMAN; INSULIN RESISTANCE; MALE; NORMAL HUMAN; OBESITY;

EID: 0031032576     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90008-1     Document Type: Article

References (69)

1. Attman P-O, Alaupovic P, Gustafson A: Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 32:368-375, 1987
2. Attman P-O, Gustafson A, Alaupovic P, Wang CS: Lipid metabolism in patients with chronic renal failure in the predialytic phase. Contrib Nephrol 65:24-32, 1988
3. Avram MM, Goldwasser P, Burrell D, Antigneni A, Fein P, Mittman N: The uremic dyslipidemia: A cross sectional and longitudinal study. Am J Kidney Dis 20:324-335, 1992
4. Ma KW, Greene EL, Raij L: Cardiovascular risk factors in chronic renal failure and hemodialysis population. Am J Kidney Dis 19:505-513, 1992
5. Bagdade JD, Porte D Jr, Bierman EL: Hypertriglyceridemia: A metabolic consequence of chronic renal failure. N Engl J Med 279:181-185, 1968
6. Brunzell JD, Albers JJ, Haas LB, Goldberg AP, Agadoa L, Sherrard DJ: Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 26:903-910, 1977
7. Cheung AK, Wu LL, Kablitz C, Leypoldt J: Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 22:271-276, 1993
8. Rubies-Prat J, Espinel E, Joven J, Ras MR, Pira L: High density lipoprotein subfractions in chronic uremia. Am J Kidney Dis 9:60-65, 1987
9. Senti M, Romero R, Pedro-Botet J, Pelegri A, Nogues X, Rubies-Prat J: Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 41:1394-1399, 1992
10. Bergesio F, Monzani G, Ciuti R, Serrato A, Benucci A, Frizzi V, Salvador M: Lipids and apolipoproteins change during the progression of chronic renal failure. Clin Nephrol 38:264-270, 1992
11. O'Neal D, Lee P, Murphy B, Best JD: Low density lipoprotein (LDL) particle size distribution in end stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Am J Kidney Dis 27:84-91, 1996
12. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM: Low density lipoprotein subclass pattern and the risk of myocardial infarction. JAMA 260:1917-1921, 1988
13. Reaven GM, Chen Y-DI, Jeppesen J, Maheux P, Krauss RM: Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 92:141-146, 1993
14. Schmitz O, Alberti K, Christensen N, Hasling C, Hjollund E, Beck-Nielsen H, Ovskov H: Insulin resistance in glucose homeostasis in uremia as assessed by the hyperinsulinemic euglycaemic clamp technique. Metabolism 34:465-473, 1985
15. DeFronzo RA, Smith D, Alvestrand A: Insulin action in uremia. Kidney Int 16:8102-104, 1983
16. Frayn KN: Insulin resistance and lipid metabolism. Curr Opin Lipidol 4:197-204, 1993
17. Chan MK, Persaud J, Varghese Z, Moorhead JF: Pathogenetic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int 25:812-818, 1984
18. Attman P-O, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21:573-592, 1993
19. Feinleib M: Epidemiology of obesity in relation to health hazards. Ann Intern Med 103:1019-1024, 1985
20. Fujioka S, Matsuzawa Y, Tokunaga K, Tarai S: Contribution of intraabdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:54-59, 1987
21. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L: Distribution of adipose tissue and risk of cardiovascular disease and death: A 12 year follow up of participants in the population study of women in Gothenberg, Sweden. BMJ 289:1257-1261, 1984
22. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C: Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 10:497-511, 1990
23. Donahue RP, Abbot RD, Bloom E, Reed DM, Yano L: Central adiposity and coronary heart disease risk in men. Lancet 1:822-824, 1987
24. Anderson AJ, Sobocinski KA, Freedman S, Barboriak JJ, Rimm AA, Gruchow HW: Body fat distribution, plasma lipids, and lipoproteins. Arteriosclerosis 8:88-94, 1988
25. Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK: Hyperinsulinemia, upper body adiposity and cardiovascular risk factors in non-diabetics. Metab Clin Exp 37:338-345, 1988
26. Peiris AN, Struve MF, Mueller RA, Lee MB: Glucose metabolism in obesity: Influence of body fat distribution. J Clin Endocrinol Metab 67:760-767, 1988
27. Galvin P, Ward G, Walters J, Pestell R, Koschmann M, Vaag A, Martin I, Best JD, Alford F: A simple method for quantitation of insulin sensitivity and insulin release from an intravenous glucose tolerance test. Diabetic Med 9:921-928, 1992
28. Albano J, Ekins R, Martiz G, Turner R: A sensitive precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free moieties. Acta Endocrinol (Copenh) 70:487-509, 1972
29. Martin IK, Weber KM, Boston RC, Alford FP, Best JD: The effects of epinephrine infusion on determinants of intravenous glucose tolerance in dogs. Am J Physiol 18:E668-E673, 1988
30. Goldstein DE: Recent advances in glycosylated hemoglobin measurements. Crit Rev Clin Lab Sci 21:187-228, 1984
31. Chung BH, Segrest JP, Ray MJ, Brunzell JD, Hokanson JE, Krauss RM, Beaudrie K, Cone JT: Single vertical spin density gradient ultracentrifugation, in Segrest JP, Albers JJ (eds): Methods in Enzymology. San Diego, CA, Academic, 1986, pp 181-209
32. Krauss RM, Burke DJ: Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23:97-104, 1982
33. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J: Insulin resistance in uremia. J Clin Invest 67:563-568, 1981
34. Schmitz O, Alberti K, Christensen N, Hasling E, Hjollund E, Beck-Nielsen H, Orskov H: Aspects of glucose homeostasis in uremia as assessed by the hyperinsulinemic euglycemic clamp technique. Metabolism 34:465-473, 1985
35. DeFronzo RA, Andres P, Edgar P, Walker GW: Carbohydrate metabolism in uremia: A review. Medicine 52:469-481, 1973
36. Oimomi M, Ishikawa K, Kawasaki T, Kubota S, Yoshimura Y, Baba S: Carbamylation of hemoglobin in renal failure and clinical aspects. Metabolism 33:999-1002, 1984
37. Akmal M, Massry SG, Goldstein DA, Fanti P, Weisz A, Defronzo R: Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest 75:1037-1044, 1985
38. Mak RHK: Amelioration of hypertension and insulin resistance by 1,25 dihydroxycholecalciferol in hemodialysis patients. Pediatr Nephrol 6:377-382, 1992
39. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H: Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 41:1653-1661, 1992
40. Fujioka S, Matsuzawa Y, Tokunaga K, Kawamoto T, Kobatake T, Keno Y, Kotani K, Yoshida S, Tarui S: Improvement of glucose and lipid metabolism associated with selective reduction of intraabdominal visceral fat in premenopausal women with visceral obesity. Int J Obes 15:853-859, 1991
41. Evans DJ, Hoffman RG, Kalkhoff RK, Kissebah AH: Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women. Metabolism 33:68-75, 1984
42. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U: Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 72:1150-1162, 1983
43. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R: Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels, but negatively with testosterone levels. Metab Clin Exp 39:897-901, 1990
44. Pouliot MC, Despres JP, Nadeau A, Moorjani S, Prud'Homme D, Lupien PJ, Tremblay A, Bouchard C: Visceral obesity in men: Associations with glucose intolerance, plasma insulin, and lipoprotein levels. Diabetes 41:826-834, 1992
45. Rebuffe-Scrive M, Anderson B, Olbe L, Bjorntorp P: Metabolism of adipose tissue of intraabdominal depots of non-obese men and women. Metabolism 38:453-461, 1989
46. Hellmer J, Marcus C, Sonnenfeld T, Arner P: Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells. J Clin Endocrinol Metab 75:15-20, 1992
47. Arner P, Hellstrom L, Wahrenberg H, Bronengard M: Beta-adrenergic receptor expression in human fat cells from different regions. J Clin Invest 86:1595-1600, 1990
48. Bounder J, Kager L, Ostman J, Arner P: Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes 32:117-122, 1983
49. Bolinder J, Engfeldt P, Ostman J, Arner P: Site differences in insulin receptor binding and insulin action in subcutaneous fat of obese females. J Clin Endocrinol Metab 57:455-459, 1983
50. Bjorntorp P: Metabolic implications of body fat distribution. Diabetes Care 14:1132-1143, 1991
51. Bjorntorp P: "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 10:493-497, 1990
52. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 2:785-789, 1963
53. Cattran DC, Fenton SSA, Wilson DR, Steiner G: Defective triglyceride removal in lipemia associated with peritoneal dialysis and hemodialysis. Ann Intern Med 85:29-33, 1976
54. Savdie E, Gibson JC, Crawford GA, Simons LA, Mahony JF: Impaired triglyceride clearance as a feature of both uremic and posttransplant triglyceridemia. Kidney Int 18:774-782, 1980
55. Roullett J-B, Lacour B, Yvert JP, Prat JJ, Drucke T: Factors in increase of triglyceride rich lipoproteins in uremic rats. Kidney Int 27:420-425, 1985
56. Applebaum-Bowden D, Goldberg AP, Hazzard WR, Sherrard DJ, Brunzell JD, Huttunen JK, Nikkila EA, Ehnholm C: Postheparin plasma triglyceride lipases in chronic hemodialysis: Evidence for a role for hepatic lipase in lipoprotein metabolism. Metabolism 28:917-924, 1979
57. Karhapaa P, Malkki M, Laakso M: Isolated low HDL cholesterol. Diabetes 43:411-417, 1994
58. Murase T, Cattran DC, Rubenstein B, Steiner G: Inhibition of lipoprotein lipase by uremic plasma, a possible cause of hypertriglyceridemia. Metabolism 24:1279-1286, 1975
59. Crawford GA, Mahony JF, Stewart JH: Impaired lipoprotein lipase activation by uremic and posttransplant sera. Clin Sci 60:73-80, 1981
60. Attman PO, Alaupovic P: Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 57:401-410, 1991
61. Wakabayashi I, Okubo M, Shimada H, Sato N, Koide A, Marumo F, Hakamura H: Decreased VLDL apoprotein CII/apoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment. Metabolism 36:815-820, 1987
62. Alsayed N, Rebourcet R: Abnormal concentrations of CII, CIII, and E apolipoproteins among apolipoprotein B containing, B free, and AI containing lipoprotein particles in hemodialysis patients. Clin Chem 37:387-393, 1991
63. Guarnieri G, Moracchiello M, Campanacci L, Ursini F, Ferri L, Valente M, Gregolin C: Lecithin cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int 13:S26-S30, 1978 (suppl 8)
64. Dieplinger H, Schoenfeld PY, Fielding CJ: Plasma cholesterol metabolism in end stage renal disease - Difference between treatment by hemodialysis or peritoneal dialysis. J Clin Invest 77:1071-1083, 1986
65. Corboy J, Sutherland WH, Walker RJ, Robertson MC, Cox CM: Cholesteryl ester transfer in patients with renal failure or renal transplant. Kidney Int 46:1147-1153, 1994
66. Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S, Blum M, Peer G, Iaina A: Severe defect in clearing postprandial chylomicron remnants in dialysis patients. Kidney Int 42:1247-1252, 1992
67. Dieplinger H, Lobentanz E-M, Konig H, Graf H, Sandholzer C, Matthys E, Rosseneu M, Utermann G: Plasma apolipoprotein A IV metabolism in patients with chronic renal disease. Eur J Clin Invest 22:166-174, 1992
68. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
69. Ferrannini E, Haffner SM, Mitchell BD, Stern MP: Hyperinsulinemia: The key feature of a cardiovascular and metabolic syndrome. Diabetologia 34:416-422, 1991